Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Argenta and Pcovery Announce Drug Discovery Collaboration

Published: Tuesday, July 16, 2013
Last Updated: Tuesday, July 16, 2013
Bookmark and Share
Under the terms of the agreement, Argenta will provide medicinal chemistry and computer-aided drug design services to assist Pcovery.

Argenta announces that it has signed a collaboration agreement with Pcovery. The collaboration is funded by a Wellcome Trust Seeding Drug Discovery (SDD) award.

According to the US Centers for Disease Control and Prevention*, mycotic (fungal) infections pose a growing threat to public health. Opportunistic infections such as cryptococcosis and aspergillosis are becoming increasingly problematic due to the rising number of people with weakened immune systems, such as cancer patients, transplant recipients, and people with HIV/AIDS. In addition, hospital-associated infections such as candidemia are a leading cause of bloodstream infections in the United States and advances and changes in healthcare practices can provide opportunities for new and drug-resistant fungi to emerge in hospital settings. Finally, community-acquired infections such as coccidioidomycosis (valley fever), blastomycosis, and histoplasmosis are caused by fungi that are abundant in the environment and whose prevalence may be being increased by climate change. Consequently, there is a need for novel anti-fungal agents that can tackle threats such as these.

Pcovery is focused on the development of safe and efficient broad-spectrum anti-fungal agents using structure-based drug discovery to target membrane proteins. Pcovery is a spin-out company from the PUMPkin Centre (Centre for Membrane Pumps in Cells and Disease) at Aarhus University and Copenhagen University and was established in April 2009. The company’s investors include Novo Seeds and Østjysk Innovation.

Dr John Montana, Managing Director of Argenta, commented, “Argenta is pleased to announce this collaboration with Pcovery, which represents the third Wellcome Trust SDD-funded project aided by Argenta during the funding rounds in 2012. The Argenta team looks forward to working with Pcovery towards achieving the project goals over the coming months”.

Mr Casper Tind Hansen, CEO of Pcovery says, “We look forward very much to working with the highly skilled and capable Argenta team to progress what will hopefully be a novel class of anti-fungal drugs for invasive fungal infections. The Argenta team has already been a big help in securing the Wellcome Trust SDD funding.” 

*US Centers for Disease Control and Prevention website, http://www.cdc.gov/fungal/, accessed 14 May 2013.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More Than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Argenta, Antabio Achieve Milestone in Anti-bacterial Drug Discovery Collaboration
Argenta has achieved a milestone with its collaboration partner Antabio in an anti-bacterial drug discovery project funded by the Wellcome Trust.
Monday, March 10, 2014
Argenta Announces Record Year for Peer-Reviewed Publications
Publications have been co-authored with clients such as Genentech, AstraZeneca and Corcept.
Tuesday, December 10, 2013
Argenta Announces Fourth Extension of Drug Discovery Collaboration with Genentech
Agreement covers a portfolio of projects that utilizes Argenta's drug discovery expertise.
Monday, October 14, 2013
Argenta Announces Integrated Drug Discovery Collaboration with Boehringer Ingelheim
Programme will focus on respiratory disease.
Wednesday, April 17, 2013
Argenta and ANTABIO Announce Drug Discovery Collaboration
Programme will focus on novel antibacterial agents.
Friday, February 08, 2013
Argenta in Respiratory Pact with Pulmagen
Subcontracting agreement to perform integrated services on two respiratory projects.
Thursday, July 07, 2011
Argenta Delivers Preclinical Candidate for Wellcome Trust Funded Anti-Aging Project
The three-year project aimed at identifying selective inhibitors of the 11beta-HSD1 enzyme resulted in the identification of a lead candidate.
Tuesday, October 19, 2010
Argenta Expands Collaboration with Genentech to Include BioFocus
Under the amendment, BioFocus will provide Genentech with integrated medicinal chemistry, in vitro biology and ADME services.
Thursday, September 16, 2010
Argenta Discovery Announces Two-Year Extension of Major Drug Discovery Collaboration with Genentech
This is the second extension of the contract drug discovery agreement since the first collaboration was announced in December 2005.
Friday, May 22, 2009
Argenta Discovery and Porsolt Join Forces to Provide CNS and Pain Contract Drug Discovery Services
The collaboration enables Argenta and Porsolt to undertake fully integrated CNS and pain-focused drug discovery programmes for clients.
Wednesday, May 20, 2009
Argenta Discovery and PRECOS Establish Cancer Drug Discovery Alliance
The alliance will provide exceptional cancer drug discovery services and expertise on a fee-for-service basis.
Thursday, February 19, 2009
Argenta Discovery Announces the Initiation of a Phase II Clinical Trial with ADC4022
The Phase II study is a multi-centre, randomized, double-blind, placebo-controlled study to evaluate the effect of inhaled ADC4022.
Monday, March 10, 2008
Argenta Discovery Announces Two-Year Extension of Major Drug Discovery Collaboration with Genentech
The two programmes under the agreement utilize Argenta's expertise to discover new chemical entities acting against undisclosed drug targets defined by Genentech.
Wednesday, October 24, 2007
Argenta Discovery Announces Contract Drug Discovery Collaboration with BioTie Therapies
Scientists from the two companies will exploit Argenta’s expertise in medicinal chemistry, computer-aided drug design and early ADME to advance one of BioTie’s therapeutics programmes.
Friday, April 06, 2007
Argenta Announces Collaboration with PainCeptor
Scientists from the two companies will exploit Argenta’s expertise in computer-aided drug design and medicinal chemistry.
Monday, May 01, 2006
Scientific News
Releasing Cancer Cells for Better Analysis
A new device developed at the University of Michigan could provide a non-invasive way to monitor the progress of an advanced cancer treatment.
Releasing Cancer Cells for Better Analysis
A new device developed at the University of Michigan could provide a non-invasive way to monitor the progress of an advanced cancer treatment.
Apricot Kernels Pose Risk of Cyanide Poisoning
Eating more than three small raw apricot kernels, or less than half of one large kernel, in a serving can exceed safe levels. Toddlers consuming even one small apricot kernel risk being over the safe level.
Cell Transplant Treats Parkinson’s in Mice
A University of Wisconsin—Madison neuroscientist has inserted a genetic switch into nerve cells so a patient can alter their activity by taking designer drugs that would not affect any other cell.
Understanding Female HIV Transmission
Glowing virus maps points of entry through entire female reproductive tract for first time.
Genetic Markers Influence Addiction
Differences in vulnerability to cocaine addiction and relapse linked to both inherited traits and epigenetics, U-M researchers find.
Lab-on-a-Chip for Detecting Glucose
By integrating microfluidic chips with fiber optic biosensors, researchers in China are creating ultrasensitive lab-on-a-chip devices to detect glucose levels.
A lncRNA Regulates Repair of DNA Breaks in Breast Cancer Cells
Findings give "new insight" into biology of tough-to-treat breast cancer.
COPD Linked to Increased Bacterial Invasion
Persistent inflammation in COPD may result from a defect in the immune system that allows airway bacteria to invade deeper into the lung.
Detection of HPV in First-Void Urine
Similar sensitivity of HPV test on first void urine sample compared to cervical smear.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!